Subject: A retrospective cross-sectional, observational survey study to analyse role of Quetiapine in the treatment of acute manic episode associated with bipolar disorder.
Bipolar disorder, previously known as manic depressive illness, is a severe chronic mood disorder characterised by episodes of mania, hypomania, and alternating or intertwining episodes of depression. No biomarker has yet been approved for diagnosis of any mental disorder and clinical criteria endure 1 .The most widely acknowledged diagnostic classifications are the 10th revision of the International Classification of Diseases (ICD-10)2 and the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).3
Manic or hypomanic episodes are states of elevated mood and increased motor drive that are finite in time and differ in severity and length. Although a manic episode impairs social or occupational functioning and might encompass psychotic symptoms or even lead to hospital admission.4
The bipolar spectrum disorders are BD type 1 (BD-1), type 2 (BD-2), cyclothymia and not otherwise specified BD5. Although depressive symptoms and episodes are more common, manic episodes are required for the diagnosis. According to the latest edition of the American Psychiatric Association’s (APA) The Diagnostic and Statistical Manual of Mental Disorders (DSM 5), during manic episodes, patients exhibit elevated or irritable mood, hyperactivity, increased speed of speech or need to talk, flight of ideas, inflated self-esteem, decreased need for sleep, distractibility, and interest in risky activities.
Quetiapine monotherapy for mania associated with bipolar disorder combined analysis of two international, double-blind, randomised, placebo-controlled studies showed a significant improvement in Young Mania Rating Scale (YMRS) score was observed from Day 4 (p = 0.021) onward in the quetiapine group compared with placebo. The treatment advantage of quetiapine over placebo continued to increase to Day 21 (p < 0.001) and Day 84 (p < 0.001). Significantly more quetiapine-treated than placebo-treated patients achieved a response (p < 0.001).6
In the current Canadian treatment algorithm (CANMAT)7, lithium, quetiapine, valproate, asenapine, aripiprazole, paliperidone, risperidone and cariprazine monotherapies are recommended as the first step of treatment for acute mania, and so are quetiapine, aripiprazole, risperidone and asenapine to be used in combination lithium and valproate.
Quetiapine tablets (Qutipin) are marketed by Sun Pharmaceutical Industries Ltd. Although every product is marketed only after regulatory approval, it is important to know how it performs in day-to-day practice of individual medical practitioners. For this purpose, we have planned to conduct a survey to analyse role of quetiapine (Qutipin) in the treatment of acute manic episode associated with bipolar disorder.
We invite you to participate in this data collection activity. All you need to do is to report on a standard form your experience with quetiapine (Qutipin) in the normal course of your practice. If you agree to participate, you will need to fill data collection forms (which we call DCF).
We trust you and we are partners in promoting effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}